Cancer research faces significant biological, technological, and systemic limitations that hinder the development of effective therapies and improved patient outcomes. Traditional preclinical models, such as 2D and 3D cell cultures, murine xenografts, and organoids, often fail to reflect the complexity of human tumor architecture, microenvironment, and immune interactions. This discrepancy results in promising laboratory findings not always translating effectively into clinical success. A core obstacle is tumor heterogeneity, characterized by diverse genetic, epigenetic, and phenotypic variations within tumors, which complicates treatment strategies and contributes to drug resistance. Hereditary malignancies and cancer stem cells contribute strongly to generating this complex panorama. Current early detection technologies lack sufficient sensitivity and specificity, impeding timely diagnosis. The tumor microenvironment, with its intricate interactions and resistance-promoting factors, further promotes treatment failure. Additionally, we only partially understand the biological processes driving metastasis, limiting therapeutic advances. Overcoming these barriers involves not only the use of new methodological approaches and advanced technologies, but also requires a cultural effort by researchers. Many cancer studies are still essentially observational. While acknowledging their significance, it is crucial to recognize the shift from deterministic to indeterministic paradigms in biomedicine over the past two to three decades, a transition facilitated by systems biology. It has opened the doors of deep metabolism where the functional processes that control and regulate cancer progression operate. Beyond biological barriers, systemic challenges include limited funding, regulatory complexities, and disparities in cancer care access across different populations. These socio-economic factors exacerbate research stagnation and hinder the translation of scientific innovations into clinical practice. Overcoming these obstacles requires multidisciplinary collaborations, advanced modeling techniques that better emulate human cancer, and innovative technologies for early detection and targeted therapy. Strategic policy initiatives must address systemic barriers, promoting health equity and sustainable research funding. While the complexity of cancer biology and systemic challenges are formidable, ongoing scientific progress and collaborative efforts inspire hope for breakthroughs that can transform cancer diagnosis, treatment, and survival outcomes worldwide.
癌症研究面临着显著的生物学、技术及系统性局限，这些障碍制约了有效疗法的开发与患者预后的改善。传统临床前模型（如二维/三维细胞培养、小鼠异种移植模型及类器官）往往难以反映人类肿瘤结构、微环境与免疫互作的复杂性。这种差异导致有前景的实验室发现无法有效转化为临床成功。肿瘤异质性是核心障碍之一，其表现为肿瘤内部遗传学、表观遗传学及表型的多样性变异，这种特性不仅使治疗策略复杂化，更导致耐药性产生。遗传性恶性肿瘤与癌症干细胞在这一复杂格局的形成中起着关键作用。现有早期检测技术缺乏足够的灵敏度与特异性，阻碍了及时诊断。肿瘤微环境通过其复杂的相互作用及耐药促进因子，进一步加剧治疗失败。此外，我们对驱动转移的生物学过程认知尚不全面，限制了治疗进展。突破这些障碍不仅需要采用新的方法论与先进技术，更要求研究者进行思维范式的革新。当前许多癌症研究本质上仍停留于观察性描述。在肯定其价值的同时，必须认识到过去二三十年间生物医学已从确定性范式转向非确定性范式，这一转变由系统生物学推动，开启了深入探索调控癌症进展的功能性代谢过程的大门。除生物学障碍外，系统性挑战还包括科研经费不足、监管体系复杂以及不同人群癌症医疗可及性差异等问题。这些社会经济因素加剧了研究停滞，阻碍科学创新向临床实践的转化。克服这些困境需要多学科协作、能更好模拟人类癌症的先进建模技术，以及用于早期检测与靶向治疗的创新技术。战略性政策举措必须着力解决系统性障碍，促进健康公平与可持续的研究资助。尽管癌症生物学的复杂性与系统性挑战十分严峻，但持续的科学进展与协作努力为全球癌症诊断、治疗及生存预后的突破性变革带来了希望。
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
肿瘤(癌症)患者之家